The ILC2/IL-13 axis modulates T cell-to-MDSC balance to drive an immunosuppressive microenvironment, whereas the inhibition of ILC2/IL-13 axis improves bladder cancer treatment (125). Here, IL13 is linked to urinary bladder carcinoma.